Free Trial

Aprea Therapeutics (APRE) Stock Price, News & Analysis

+0.28 (+5.58%)
(As of 05/24/2024 08:49 PM ET)
Today's Range
50-Day Range
52-Week Range
4,600 shs
Average Volume
24,988 shs
Market Capitalization
$28.78 million
P/E Ratio
Dividend Yield
Price Target

Aprea Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
192.5% Upside
$15.50 Price Target
Short Interest
1.90% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Acquiring Shares
$71,952 Bought Last Quarter
Proj. Earnings Growth
From ($2.57) to ($0.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.82 out of 5 stars

Medical Sector

229th out of 922 stocks

Pharmaceutical Preparations Industry

99th out of 429 stocks

APRE stock logo

About Aprea Therapeutics Stock (NASDAQ:APRE)

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

APRE Stock Price History

APRE Stock News Headlines

Aprea Therapeutics Appoints Mirza As CMO
Interim Report - January-March 2024
Aprea Therapeutics CFO buys $7,362 in company stock
See More Headlines
Receive APRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$5.33 per share


Free Float
Market Cap
$28.77 million
No Data
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Oren Gilad Ph.D. (Age 56)
    Co-Founder, CEO, President & Director
    Comp: $520.84k
  • Mr. John P. Hamill CPA (Age 60)
    Senior VP, CFO, Principal Accounting Officer & Secretary
  • Dr. Dansu Li Ph.D.
    Head of Technology
  • Dr. Lars B. Abrahmsen Ph.D. (Age 67)
    Senior VP & Chief Scientific Officer
  • Dr. Michel Afargan Ph.D.
    Head of Pharmacology Development
  • Mr. Ze'ev Weiss B.Sc. (Age 62)
    C.P.A., Chief Business Advisor
  • Ms. Andrea Epstein

APRE Stock Analysis - Frequently Asked Questions

Should I buy or sell Aprea Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APRE shares.
View APRE analyst ratings
or view top-rated stocks.

What is Aprea Therapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 12 month price objectives for Aprea Therapeutics' shares. Their APRE share price targets range from $11.00 to $20.00. On average, they predict the company's share price to reach $15.50 in the next year. This suggests a possible upside of 192.5% from the stock's current price.
View analysts price targets for APRE
or view top-rated stocks among Wall Street analysts.

How have APRE shares performed in 2024?

Aprea Therapeutics' stock was trading at $4.70 at the beginning of 2024. Since then, APRE stock has increased by 12.8% and is now trading at $5.30.
View the best growth stocks for 2024 here

When is Aprea Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our APRE earnings forecast

How were Aprea Therapeutics' earnings last quarter?

Aprea Therapeutics, Inc. (NASDAQ:APRE) issued its earnings results on Tuesday, March, 26th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.36. The firm earned $0.01 million during the quarter, compared to analysts' expectations of $0.33 million. Aprea Therapeutics had a negative trailing twelve-month return on equity of 56.78% and a negative net margin of 1,317.82%.

When did Aprea Therapeutics' stock split?

Shares of Aprea Therapeutics reverse split before market open on Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aprea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN).

When did Aprea Therapeutics IPO?

Aprea Therapeutics (APRE) raised $52 million in an IPO on Thursday, October 3rd 2019. The company issued 5,000,000 shares at $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.

Who are Aprea Therapeutics' major shareholders?

Aprea Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Eyal C Attar, Gregory Alan Korbel, John P Hamill, Lars B Abrahmsen and Oren Gilad.
View institutional ownership trends

How do I buy shares of Aprea Therapeutics?

Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APRE) was last updated on 5/27/2024 by Staff

From Our Partners